Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report

China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Market Research Report 2023-2029

  • POSTDATE：Aug 19, 2023
  • PAGES：140
  • REPORT CODE：GMM1743797
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Non-Alcoholic Steatohepatitis (NASH) Drugs industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Horizon Pharma

    • Novo Nordisk

    • Gilead

    • Genfit

    • Intercept Pharmaceuticals

    • Immuron

    • Conatus Pharmaceuticals

    • Galmed Pharmaceuticals

    • Enzo Biochem

    By Type:

    • Obeticholic Acid (OCA)

    • Selonsertib & Cenicriviroc

    • Vitamin E & Pioglitazone

    • Elafibranor

    By Application:

    • Online Provider

    • Retail Pharmacy

    • Hospital Pharmacy

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview 2018-2029

    • 1.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Development Overview

    • 1.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Development History

    • 1.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Market Size (2018-2029)

    • 1.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis by Type from Production Side

      • 1.4.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Obeticholic Acid (OCA) (2018-2029)

      • 1.4.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Selonsertib & Cenicriviroc (2018-2029)

      • 1.4.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Vitamin E & Pioglitazone (2018-2029)

      • 1.4.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Elafibranor (2018-2029)

    • 1.5 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis by Application from Consumption End

      • 1.5.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Online Provider (2018-2029)

      • 1.5.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Retail Pharmacy (2018-2029)

      • 1.5.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Hospital Pharmacy (2018-2029)

    • 1.6 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis by Region

      • 1.6.1 North China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    Chapter 2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Non-Alcoholic Steatohepatitis (NASH) Drugs Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Status and Competition Analysis in 2023

      • 2.2.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Development

    Chapter 3 Non-Alcoholic Steatohepatitis (NASH) DrugsIndustry Chain Analysis

    • 3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Chain

    • 3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Non-Alcoholic Steatohepatitis (NASH) Drugs Market

    • 3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Non-Alcoholic Steatohepatitis (NASH) Drugs Market

    Chapter 4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 4.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Total Production Volume and Growth Rate from Production Side

    • 4.5 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate, by Type

      • 4.5.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Obeticholic Acid (OCA)

      • 4.5.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Selonsertib & Cenicriviroc

      • 4.5.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Vitamin E & Pioglitazone

      • 4.5.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Elafibranor

    Chapter 5 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Total Market Size and Growth Rate from Consumption End

    • 5.5 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate, by Application

      • 5.5.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Online Provider

      • 5.5.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Retail Pharmacy

      • 5.5.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Hospital Pharmacy

    Chapter 6 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Region

    • 6.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Production Value, by Region

    • 6.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume and Sales Value, by Region

    Chapter 7 North China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 7.1 North China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 7.2 North China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 8 Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 8.1 Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 8.2 Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 9 South China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 9.1 South China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 9.2 South China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 10 East China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 10.1 East China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 10.2 East China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 11 Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 11.1 Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 11.2 Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 12 Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 12.1 Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 12.2 Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 13 Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis

    • 13.1 Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type

    • 13.2 Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Horizon Pharma

        • 14.1.1 Horizon Pharma Company Profile

        • 14.1.2 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Novo Nordisk

        • 14.2.1 Novo Nordisk Company Profile

        • 14.2.2 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Gilead

        • 14.3.1 Gilead Company Profile

        • 14.3.2 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Genfit

        • 14.4.1 Genfit Company Profile

        • 14.4.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Intercept Pharmaceuticals

        • 14.5.1 Intercept Pharmaceuticals Company Profile

        • 14.5.2 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Immuron

        • 14.6.1 Immuron Company Profile

        • 14.6.2 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Conatus Pharmaceuticals

        • 14.7.1 Conatus Pharmaceuticals Company Profile

        • 14.7.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Galmed Pharmaceuticals

        • 14.8.1 Galmed Pharmaceuticals Company Profile

        • 14.8.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Enzo Biochem

        • 14.9.1 Enzo Biochem Company Profile

        • 14.9.2 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Research Conclusions

    • 15.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Market Size (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Obeticholic Acid (OCA) (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Selonsertib & Cenicriviroc (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Vitamin E & Pioglitazone (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume, Production Value and Growth Rate of Elafibranor (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Online Provider (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Retail Pharmacy (2018-2029)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume, Sales Value and Growth Rate of Hospital Pharmacy (2018-2029)

    • Figure North China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure South China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure East China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2018

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type in 2023

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Obeticholic Acid (OCA) (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Selonsertib & Cenicriviroc (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Vitamin E & Pioglitazone (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume and Growth Rate of Elafibranor (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2018

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application in 2023

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Total Market Size and Growth Rate from Consumption End

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Online Provider (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Retail Pharmacy (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Growth Rate of Hospital Pharmacy (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Region (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Value by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Value Share by Region (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Value Share by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Region (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Value by Region (2018-2023)

    • Table China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Value Share by Region (2018-2023)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Value Share by Region (2018-2023)

    • Table North China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table North China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure North China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table North China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table North China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure North China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Central China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table South China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table South China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure South China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table South China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table South China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure South China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table East China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table East China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure East China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table East China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table East China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure East China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume by Type (2018-2023)

    • Table Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Production Volume Share by Type (2018-2023)

    • Table Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume by Application (2018-2023)

    • Table Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Horizon Pharma Company Profile

    • Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Novo Nordisk Company Profile

    • Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Gilead Company Profile

    • Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Genfit Company Profile

    • Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Intercept Pharmaceuticals Company Profile

    • Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Immuron Company Profile

    • Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Conatus Pharmaceuticals Company Profile

    • Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Galmed Pharmaceuticals Company Profile

    • Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Enzo Biochem Company Profile

    • Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US